LORCASERIN

Feb. 17, 2020

Indian doctors have cautioned against the use of lorcaserin (brand name Belviq or Belviq XR), a weight-loss drug that the U.S. Food and Drug Administration (FDA) recently said is linked to a “possible increased risk of cancer.”

About:

  • Doctors warn against use of weight-loss drug. 

  • Lorcaserin, marketed under the brand name Belviq is a weight-loss drug developed by Arena Pharmaceuticals.

  • It reduces appetite by activating a type of serotonin receptor in a region of the brain called the hypothalamus, which is known to control appetite.

  • Lorcaserin is used long term for weight loss in those who are obese.

  • The U.S. FDA requested the drug manufacturer to voluntarily withdraw lorcaserin, after a post-marketing trial with more than 12,000 subjects revealed an increased occurrence of cancer. 

Source : The Hindu